CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 270 target
Drug / intervention
s-1 plus cisplatin +1 moredrug
Likely dose
s-1 plus cisplatin 80 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01198392
NCT01198392Phase 3Unknown
CompareCT.gov

A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer

Sun Yat-sen University·interventional·Posted Sep 10, 2010·Updated Jul 25, 2011

In Brief

A Phase 3 clinical trial evaluating s-1 plus cisplatin and 5-Fu plus cisplatin for Gastric Cancer. Targeting 270 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesChina
Collaborators--

Timeline

Phase 3UnknownOverdue
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2010
Enrollment StartSep 1, 2008
Primary CompletionDec 1, 2011
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 15.8 years ago

Interventions

s-1 plus cisplatindrug

S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

5-Fu plus cisplatindrug

5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.